Publications and Posters


  • Saemundsson A, Xu LD, Meisgen F, Cao R, Ahlgren G. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients. Prostate. 2023 Mar 29. doi: 10.1002/pros.24530.
    • Röbeck P, Xu L, Ahmed D, Dragomir A, Dahlman P, Häggman M, Ladjevardi S. P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer. Prostate. 2023 Mar 20. doi: 10.1002/pros.24523.
    • Söderdahl F, Xu LD, Bring J, Häggman M. A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality. Res Rep Urol. 2022 May 11;14:203-217. doi: 2147/RRU.S358169.
    • Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS One. 2016 Jan 5;11(1):e0145545. doi: 1371/journal.pone.0145545.
    • Peng Z, Andersson K, Lindholm J, Bodin I, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS One. 2014 Oct 8;9(10):e109610. doi: DOI: 10.1371/journal.pone.0109610
    • Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):81-90. doi: 10.1038/pcan.2013.57.